Upcoming Webinar:Join us for Sustainability 100+ Dialogues 2021-Maharashtra Roundtable& know how the state is progressing on climate action
you are here: HomeNewsBusiness

Glenmark Pharmaceuticals gets USFDA nod for Fingolimod capsules

"Glenmark Pharmaceuticals Inc, USA has been granted final approval by the United States Food and Drug Administration (USFDA) for Fingolimod Capsules, 0.5 mg, the generic version of Gilenya capsules, 0.5 mg, of Novartis Pharmaceuticals Corporation," the drug major said in a filing to BSE.

June 19, 2020 / 10:03 AM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug major Glenmark Pharmaceuticals on Friday said it has received final nod from the health regulator for Fingolimod capsules. The capsules are used in the treatment of adult patients with relapsing forms of multiple sclerosis.

"Glenmark Pharmaceuticals Inc, USA has been granted final approval by the United States Food and Drug Administration (USFDA) for Fingolimod Capsules, 0.5 mg, the generic version of Gilenya capsules, 0.5 mg, of Novartis Pharmaceuticals Corporation," the drug major said in a filing to BSE.

According to IQVIA sales data for the 12-month period ending April 2020, the Gilenya Capsules, 0.5 mg market achieved annual sales of approximately USD 2.1 billion, the company said.

Glenmark's current portfolio consists of 164 products authorised for distribution in the US marketplace and 44 abbreviated new drug applications pending approval with the USFDA.

Shares of Glenmark Pharmaceuticals were trading at Rs 411.20 a piece on BSE in morning trade, up 1.44 per cent from their previous close.
PTI
first published: Jun 19, 2020 09:57 am

stay updated

Get Daily News on your Browser
Sections
ISO 27001 - BSI Assurance Mark